STERIS plc (STE)

STERIS Plc's stock has experienced fluctuations, outperforming the S&P 500 Index by +3.34% over the past six months as of July 11, 2025. Morgan Stanley upgraded STERIS to "Overweight" in July 2025, leading to a rise in shares. The stock has seen a slight fall of -1.11% in the previous week and -5.22% over the last month as of July 21, 2025. In February 2025, STERIS lowered its annual profit forecast due to the impact of a stronger dollar. In May 2025, STERIS announced its fiscal 2025 fourth-quarter and full-year financial results, with the Healthcare segment showing strong revenue growth. The company completed the divestiture of its Dental segment in the first quarter of fiscal 2025 and has been actively managing its debt, cutting long-term debt by 38.5% as of the fiscal fourth quarter of 2025.

While specific seasonal patterns are not explicitly detailed, demand for STERIS's products and services is consistently driven by increased concern over hospital-acquired infections, rising demand for medical procedures, and increased regulatory scrutiny of cleaning and validation processes in the pharmaceutical industry. The Healthcare segment's organic growth is driven by continuous procedure volume growth in the United States, favorable pricing, and market share gains. Bioprocessing demand has shown signs of stabilization, with expectations for meaningful growth to return in the second half of fiscal 2025. Macroeconomic challenges, including government and insurance company efforts to contain healthcare costs, and increases in raw material prices, can impact demand and production costs. Supply chain normalization has occurred, with lead times for STERIS's products returning to pre-pandemic levels as of the fourth quarter of fiscal 2024.

STERIS Plc is a global leader in infection prevention and procedural products and services, primarily serving the healthcare, pharmaceutical, and medical device industries. The company operates within the Healthcare sector and the Medical Devices industry, providing a comprehensive range of products and services focused on infection prevention, contamination control, and surgical and critical care technologies. Its major products and services are categorized into Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. STERIS generates revenue through sales of services, consumables, and equipment.

STERIS has a significant global presence with operations across North America, Latin America, Europe, Asia, and the Middle East & Africa. The majority of its revenue is derived from North America, specifically the United States, with other regions contributing a smaller percentage. The company employs a direct sales force in developed markets and utilizes distributors in other selected markets.

STERIS's brand reputation has been significantly impacted by legal challenges in the past year. The company is facing hundreds of lawsuits alleging harm from its use of ethylene oxide (EtO) in medical device sterilization. These lawsuits claim exposure to EtO emissions led to cancer and other illnesses.

Institutional investors hold a significant majority of STERIS Plc's shares. As of December 31, 2024, institutional investors owned 93.22% of the total outstanding shares, while insiders owned 0.93%, and retail investors held the remaining 5.85%. Major institutional shareholders include Vanguard Group Inc., BlackRock Inc., Massachusetts Financial Services Co, WCM Investment Management LLC, State Street Corp, Morgan Stanley, and Generation Investment Management Llp.